Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Section 32
AddedFeb 13, 2024
UpdatedJul 16, 2026
Section 32

Section 32

Operating

Section 32, a CA-based venture fund, invests in tech, biotech, healthcare, and life sciences.

Location
San Diego, CA, US
Founded
2017
Firm
Compare
Portfolio
Employees
News
Website

Investments

Puzzle Financial
Puzzle Financial

Total Raised

$45.3M

Rounds

4

Series Unknown$30MNovember 2023
Rome Therapeutics
Rome Therapeutics

Total Raised

$199M

Rounds

3

Series B$72MSeptember 2023
Inceptive
Inceptive

Total Raised

$120M

Rounds

2

Series A$100MSeptember 2023
Endor Labs
Endor Labs

Total Raised

$95M

Rounds

3

Series A$70MAugust 2023
Octave Bioscience
Octave Bioscience

Total Raised

$91M

Rounds

6

Series B$32.5MJuly 2023
AltPep
AltPep

Total Raised

$76M

Rounds

2

Series B$52.9MJune 2023
Delve Bio
Delve Bio

Total Raised

$35M

Rounds

1

Series A$35MJune 2023
Function Oncology
Function Oncology

Total Raised

$28M

Rounds

1

Series A$28MApril 2023
Faro Health
Faro Health

Total Raised

$35M

Rounds

2

Series A$20MFebruary 2023
Forward Networks
Forward Networks

Total Raised

$112.1M

Rounds

4

Series D$50MJanuary 2023
MedCrypt
MedCrypt

Total Raised

$34.4M

Rounds

6

Series B$25MNovember 2022
Neocis
Neocis

Total Raised

$183.1M

Rounds

9

Series D$40MOctober 2022
Stairwell
Stairwell

Total Raised

$69.5M

Rounds

5

Series B$45MOctober 2022
Nested Therapeutics
Nested Therapeutics

Total Raised

$125M

Rounds

2

Series A$90MOctober 2022
Autobahn Therapeutics
Autobahn Therapeutics

Total Raised

$108.7M

Rounds

2

Series Unknown$32.7MSeptember 2022
Spectral
Spectral

Total Raised

$29.8M

Rounds

3

Series Unknown$23MAugust 2022
Inworld AI
Inworld AI

Total Raised

$125.7M

Rounds

6

Series A$50MAugust 2022
BigHat Biosciences
BigHat Biosciences

Total Raised

$99.3M

Rounds

4

Series B$75MJuly 2022
Phaidra
Phaidra

Total Raised

$30.5M

Rounds

3

Series A$25MJuly 2022
Swadesh
Swadesh
Series Unknown

Total Raised

$2.4M

Rounds

4

Pre-Seed$2.3MJuly 2022
Manifold Bio
Manifold Bio

Total Raised

$45.4M

Rounds

3

Series A$40MJune 2022
Character Biosciences
Character Biosciences

Total Raised

$27M

Rounds

4

Series A$18MMay 2022
Legacy
Legacy
Series B

Total Raised

$45M

Rounds

5

Series B$25MMay 2022
Moma Therapeutics
Moma Therapeutics

Total Raised

$236M

Rounds

2

Series B$150MMay 2022
Aspen Neuroscience
Aspen Neuroscience

Total Raised

$264M

Rounds

4

Series B$147.5MMay 2022